ELI LILLY & CO. said that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion recommending the granting of a conditional marketing authorization for olaratumab, in combination with doxorubicin, for the treatment of adults in the European Union with advanced soft tissue sarcoma not amenable to curative treatment with...
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
